The p63 Protein Isoform Np63 Inhibits Epithelial-Mesenchymal Transition in Human Bladder Cancer Cells: ROLE OF MIR-205
The University of Texas M.D. Anderson Cancer Center, United States Journal of Biological Chemistry
(Impact Factor: 4.57).
12/2012; 288(5). DOI: 10.1074/jbc.M112.408104
Epithelial-mesenchymal transition (EMT) is a physiological process that plays important roles in tumor metastasis, stemness, and drug resistance. EMT is typically characterized by the loss of the epithelial marker E-cadherin and increased expression of EMT-associated transcriptional repressors, including ZEB1 and ZEB2. The miR-200 family and miR-205 prevent EMT through suppression of ZEB1/2. p53 has been implicated in the regulation of miR-200c, but the mechanisms controlling miR-205 expression remain elusive. Here we report that the p53 family member and p63 isoform, Np63α, promotes miR-205 transcription and controls EMT in human bladder cancer cells. Np63α, E-cadherin and miR-205 were co-expressed in a panel of bladder cancer cell lines (n=28) and a cohort of primary bladder tumors (n=98). Stable knockdown (KD) of Np63α in the epithelial bladder cancer cell line UM-UC6 decreased the expression of miR-205 and induced the expression of ZEB1/2, effects that were reversed by expression of exogenous miR-205. Conversely, overexpression of Np63α in the mesenchymal bladder cancer cell line UM-UC3 induced miR-205 and suppressed ZEB1/2. Np63α KD reduced the expression of the primary and mature forms of miR-205 and the miR-205 host gene (miR-205HG) and decreased binding of RNA Pol II to the miR-205HG promoter, inhibiting miR-205HG transcription. Finally, high miR-205 expression was associated with adverse clinical outcomes in bladder cancer patients. Together, our data demonstrate that Np63α-mediated expression of miR-205 contributes to the regulation of EMT in bladder cancer cells and identify miR-205 as a molecular marker of the lethal subset of human bladder cancers.
Available from: Daisuke Yamaji
- "Expression of ∆NTRP63α inhibits EMT triggered by the ∆NTRP63γ isoform in normal mammary epithelial cells (Lindsay et al. 2011) and constrains EMT in bladder cancer cells (Oh et al. 2011). However, it has also been reported that ∆NTRP63α promotes EMT in normal keratinocytes (Tran et al. 2013). While it is known that TRP63 can be expressed in many types of cancer, the percentage of cancers within each type expressing TRP63 varies (Yao and Chen. "
[Show abstract] [Hide abstract]
ABSTRACT: Trp63, founding member of the Trp53 family, contributes to epithelial differentiation and is expressed in breast neoplasia. Trp63 features two distinct promoters yielding specific mRNAs encoding two major TRP63 isoforms, a transactivating transcription factor and a dominant negative isoform. Specific TRP63 isoforms are linked to cell cycle arrest, apoptosis, survival and epithelial mesenchymal transition. Although TRP63 overexpression in cultured cells is used to elucidate functions, little is known about Trp63 regulation in normal and cancerous mammary tissue. This study used ChIP-seq to interrogate transcription factor binding and histone modifications of the Trp63 locus in mammary tissue and RNA-seq and immunohistochemistry to gauge gene expression. H3K4me2 and H3K4me3 marks coincided only with the proximal promoter, supporting RNA-seq data showing the predominance of the dominant negative isoform. STAT5 bound specifically to the Trp63 proximal promoter and Trp63 mRNA levels were elevated upon deleting STAT5 from mammary tissue, suggesting its role as a negative regulator. The dominant negative TRP63 isoform was localized to nuclei of basal mammary epithelial cells throughout reproductive cycles, and retained in a majority of the triple negative cancers generated from loss of full-length BRCA1. Increased expression of dominant negative isoforms was correlated with developmental windows of increased progesterone receptor binding to the proximal Trp63 promoter and decreased expression during lactation was correlated with STAT5 binding to the same region. TRP63 is present in the majority of triple negative cancers resulting from loss of BRCA1 but diminished in less differentiated cancer subtypes and in cancer cells undergoing epithelial mesenchymal transition.
Endocrine Related Cancer 04/2014; 21(3). DOI:10.1530/ERC-14-0032 · 4.81 Impact Factor
Available from: Reza Safaralizadeh
- "Numerous studies investigated miRNA profiling signature of bladder carcinomas distinguishing different classes, stages of progression and outcomes (Wiklund et al., 2011; Dip et al., 2012; Wang et al., 2012; Tran et al., 2013). For instance, Neely et al. (2010) noted that a miR- 21:miR-205 expression ratio can be used to distinguish invasive and non-invasive bladder tumors. "
[Show abstract] [Hide abstract]
ABSTRACT: The recent discovery of tiny microRNAs (miRNAs) has brought about awareness of a new class of regulators of diverse pathways in many physiological and pathological processes, such as tumorigenesis. They modulate gene expression by targeting plethora of mRNAs, mostly reducing the protein yield of a targeted mRNA. With accumulation of information on characteristics of miR-205, complex and in some cases converse roles of miR-205 in tumor initiation, progression and metastasis are emerging. miR-205 acts either as an oncogene via facilitating tumor initiation and proliferation, or in some cases as a tumor suppressor through inhibiting proliferation and invasion. The aim of this review is to discuss miR-205 roles in different types of cancers. Given the critical effects of deregulated miR-205 on processes involved in tumorigenesis, they hold potential as novel therapeutic targets and biomarkers.
Asian Pacific journal of cancer prevention: APJCP 01/2014; 15(2):577-83. DOI:10.7314/APJCP.2014.15.2.577 · 2.51 Impact Factor
Available from: PubMed Central
- "In addition, TWIST1 binds directly to miR-200 and miR-205 promoters and thus may act as a repressor of miR-200 and miR-205 expression. Recently, Tran et al.  reported that high miR-205 expression is associated with adverse clinical outcomes in patients with MIBC, such as poor cancer-specific and overall survival. "
[Show abstract] [Hide abstract]
ABSTRACT: Bladder cancer (BC) is the second most common malignancy of urological organs. However, patients with non-muscle-invasive BC are at high risk of recurrence and progression into muscle-invasive BC, and the prognosis of patients with muscle-invasive BC is limited by the high rate of metastasis. The epithelial-mesenchymal transition (EMT) is characterized by loss of cell-to-cell adhesion and cell polarity and is closely associated with the invasion and metastasis of several cancers. Given the multifocality and high rates of relapse, progression, and metastasis of BC, the EMT is likely to participate in BC as well. Numerous factors associate with the EMT, and the key regulators of the EMT are E-cadherin, N-cadherin, Twist, Snail, Slug, Zeb-1, Zeb-2, vimentin, and microRNAs. This review focuses on the current concepts regarding the EMT in cancer and the evidence for involvement of the EMT in BC. Several potential EMT targets that may be useful in the treatment of BC are also described.
Korean journal of urology 10/2013; 54(10):645-650. DOI:10.4111/kju.2013.54.10.645
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.